These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 4841716)

  • 1. Cell-mediated response to a mouse leukemic subline antigenically altered following drug treatment in vivo.
    Nicolin A; Bini A; Franco P; Goldin A
    Cancer Chemother Rep; 1974; 58(3):325-30. PubMed ID: 4841716
    [No Abstract]   [Full Text] [Related]  

  • 2. Adoptive immunotherapy in BALB-c times DBA-2 Cr F1 mice bearing an immunogenic subline of L1210 leukemia.
    Nicolin A; Canti G; Goldin A
    Cancer Res; 1974 Nov; 34(11):3044-8. PubMed ID: 4424774
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Cancer Res; 1972 Jul; 32(7):1446-50. PubMed ID: 4402275
    [No Abstract]   [Full Text] [Related]  

  • 4. Surface H-2 antigen concentration requirement of somatic hybrid cells for IgM-mediated cytotoxicity.
    Rubio N
    Nature; 1974 May; 249(456):461-3. PubMed ID: 4134883
    [No Abstract]   [Full Text] [Related]  

  • 5. Cellular immune response to a drug-treated L5178Y lymphoma subline.
    Nicolin A; Bini A; Coronetti E; Goldin A
    Nature; 1974 Oct; 251(5476):654-5. PubMed ID: 4138894
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytotoxicity of vivo sensitized lymphocytes on allogeneic third-party fibroblasts differing for various regions of the H-2 complex.
    Jorgensen PN; Florentz K; Güttler F
    Transplant Proc; 1974 Mar; 6(1):95-9. PubMed ID: 4817057
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
    Nicolin A; Franco P; Testorelli C; Goldin A
    Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection for high immunogenicity in drug-resistant sublines of murine lymphomas demonstrated by plaque assay.
    Fuji H; Mihich E
    Cancer Res; 1975 Apr; 35(4):946-52. PubMed ID: 1090366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of cell-mediated transplantation reactions. II. Studies with a sensitive assay of cell-mediated cytotoxicity.
    Lake P; Sabbadini E; Sehon AH
    Immunology; 1974 Sep; 27(3):441-55. PubMed ID: 4137937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of an in vitro cytotoxicity test to studies of the effects of drugs on the cellular immune response in mice. I. Primary response.
    Fass L; Fefer A
    J Immunol; 1972 Oct; 109(4):749-53. PubMed ID: 5074330
    [No Abstract]   [Full Text] [Related]  

  • 11. Central inhibition of cellular immunity to leukemia L1210 by isoantibody.
    Mitchell MS
    Cancer Res; 1972 Apr; 32(4):825-31. PubMed ID: 4622583
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking of syngeneic effector T cells by soluble tumour antigens.
    Plata F; Levy JP
    Nature; 1974 May; 249(454):271-4. PubMed ID: 4545403
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody response, measured by a plaque assay, compared to cellular response after skin allograft in mice.
    Degiovanni G; Lejeune G
    Eur J Immunol; 1973 Oct; 3(10):653-4. PubMed ID: 4203064
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
    Rapp L; Fuji H
    Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline.
    Testorelli C; Archetti YL; Aresca P; Del Vecchio L
    Cancer Res; 1985 Nov; 45(11 Pt 1):5299-303. PubMed ID: 4053006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. II. Increased expression of tumor-associated antigens on subline cells recognized by serologic and transplantation methods.
    Fuji H; Mihich E; Pressman D
    J Natl Cancer Inst; 1979 Jun; 62(6):1503-10. PubMed ID: 286122
    [No Abstract]   [Full Text] [Related]  

  • 18. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.
    Orsini F; Pavelic Z; Mihich E
    Cancer Res; 1977 Jun; 37(6):1719-26. PubMed ID: 66985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
    Nicolin A; Fagnani R; Nicolotti G; Goldin A
    Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune inhibition of allogeneic lymphoma cells in the peritoneal cavity of mice.
    Fioretti MC; Libarati M; Bonmassar E; Cudkowicz G
    Cancer Res; 1975 Jan; 35(1):30-6. PubMed ID: 1089042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.